Rice researchers will collaborate with Houston health tech startup Motif Neurotech to develop Brain Mesh, a distributed network of minimally invasive implants in the skull. Photo via Motif Neurotech

Houston startup Motif Neurotech and several Rice research groups have been selected by the United Kingdom's Advanced Research + Invention Agency (ARIA) to participate in its inaugural Precision Neurotechnologies program. The program aims to develop advanced brain-interfacing technologies for cognitive and psychiatric conditions.

ARIA will invest $84.2 million over four years in projects that “explore and unlock new methods to interface with the human brain at the circuit level,” according to a news release.

Three of the four Rice labs will collaborate with Houston health tech startup Motif Neurotech to develop Brain Mesh, which is a distributed network of minimally invasive implants that can stimulate neural circuits and stream neural data in real time. The project has been awarded approximately $5.9 million.

Motif Neurotech was spun out of the Rice lab of Jacob Robinson, a professor of electrical and computer engineering and bioengineering and CEO of Motif Neurotech. It will be developed in collaboration with U.K.-based startup MintNeuro, which will help develop custom integrated circuits that will help to miniaturize the implants, according to a separate release.

Robinson will lead the system and network integration and encapsulation efforts for Mesh Points implants. According to Rice, these implants, about the size of a grain of rice, will track and modulate brain states and be embedded in the skull through relatively low-risk surgery.

The Rice lab of Valentin Dragoi, professor of electrical and computer engineering at Rice and the Rosemary and Daniel J. Harrison III Presidential Distinguished Chair in Neuroprosthetics at Houston Methodist, will conduct non-human primate experimental models for Brain Mesh. Kaiyuan Yang, associate professor of electrical and computer engineering who leads the Secure and Intelligent Micro-Systems Lab at Rice, will work on power and data pipeline development to enable the functional miniaturization of the Mesh Points.

“Current neurotechnologies are limited in scale, specificity and compatibility with human use,” Robinson said in a news release. “The Brain Mesh will be a precise, scalable system for brain-state monitoring and modulation across entire neural circuits designed explicitly for human translation. Our team brings together a key set of capabilities and the expertise to not only work through the technical and scientific challenges but also to steward this technology into clinical trials and beyond.”

The fourth Rice lab, led by assistant professor of electrical and computer engineering Jerzy Szablowski, will collaborate with researchers from three universities and two industry partners to develop closed-loop, self-regulating gene therapy for dysfunctional brain circuits. The team is backed by an award of approximately $2.3 million.

“Our goal is to develop a method for returning neural circuits involved in neuropsychiatric illnesses such as epilepsy, schizophrenia, dementia, etc. to normal function and maybe even make them more resilient,” Szablowski said in a news release.

Neurological disorders in the U.K. have a roughly $5.4 billion economic burden, and some estimates run as high as $800 billion annually in terms of economic disruptions in the U.S. These conditions are the leading cause of illness and disability with over one in three people impacted according to the World Health Organization.

The partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments, providing a pathway for Japanese innovators to expand in the U.S. market. Photo courtesy of TMC

TMC launches cancer-focused partnership with Japan

global collaboration

Houston's Texas Medical Center announced the launch of its new TMC Japan BioBridge and Japan-Accelerator Cancer Therapeutics and Medical Devices, or JACT, this month.

The strategic partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments and providing a pathway for Japanese innovators to expand in the U.S. market. A delegation from TMC recently visited Tokyo, and William F. McKeon, president and CEO of TMC, signed the TMC Japan BioBridge Memorandum of Understanding with Takeshi Ozane, general manager of Mitsui Fudosan, and Hitoshi Nakagama, president of the National Cancer Center of Japan.

“The launch of TMC Japan BioBridge is a vital step forward in connecting two global leaders in healthcare innovation,” McKeon says in a statement. “Japan’s leadership has demonstrated an impressive commitment to advance medical cures and life sciences technologies and through this partnership, we are opening necessary doors for Japanese researchers and innovators to access the US market and collaborate with our TMC ecosystem. Together, we aim to accelerate critical breakthroughs to make a difference for patients all around the world.”

The new JACT will offer cancer-treatment companies a structured process to prepare for a U.S. expansion and will allow for meetings with pharmaceutical companies, hospital systems and investors and provide insights on U.S. regulatory approvals. It'll focus on three key areas, according to the statement:

  1. Milestone development and financial planning
  2. Clinical and regulatory expertise
  3. Strategic partnerships and market insights

“This TMC Japan BioBridge and JACT Program will enable us to promote the advancement of start-up companies aiming to commercialize innovative medical technologies originating in Japan into the U.S." Nakagama says in a statement. "We also hope this collaboration will not be limited to our (Japan Agency for Medical Research and Development)-supported project, but will lead to further cooperation between TMC, NCC, and other Japanese institutions in various fields.”

This is the sixth international strategic partnership for the TMC. It launched its first BioBridge, which focus on partnerships to support international healthcare companies preparing for U.S. expansion, with the Health Informatics Society of Australia in 2016. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

The Bayou City ranks highly thanks to a high quality-of-living score, lack of a state income tax and state capital gains tax, and a state sales tax rate of 6.25 percent. Photo by Natalie Harms/InnovationMap

Houston scores top ranking of best cities for entrepreneurs

easy living

Houston joins Dallas and Austin in a new ranking of the 10 best U.S. cities for entrepreneurs to live.

Houston appears at No. 7 on the list, compiled by SumUp, which provides payment and banking services for businesses. In part, Bayou City ranks highly thanks to a high quality-of-living score. Houston also fares well due to the lack of a state income tax and state capital gains tax, and a state sales tax rate of 6.25 percent.

Here are the top 10 places in the U.S. for entrepreneurs to live, according to SumUp:

  1. New York City
  2. Chicago
  3. Miami
  4. Los Angeles
  5. Dallas
  6. Austin
  7. Houston
  8. Seattle
  9. Washington, D.C.
  10. Boston

SumUp, based in the United Kingdom, weighed 16 factors to come up with the ranking. These factors included tax rates, number of millionaires, internet speeds, and number of international airports.

Not surprisingly, the ranking factors featured a decidedly British slant. For instance, the ranking took into account Google and TikTok search volumes in the United Kingdom for “Moving to [city name].”

Of course, Houston offers more entrepreneurial advantages than the ones cited by SumUp. For example:

  • Rice University’s Jones Graduate School of Business ranks as the country’s No. 1 graduate entrepreneurship program, according to The Princeton Review and Entrepreneur magazine.
  • The University of Houston’s Cyvia and Melvyn Wolff Center for Entrepreneurship at the C.T. Bauer College of Business ranks as the No. 1 undergraduate entrepreneurship program, according to The Princeton Review and Entrepreneur magazine.
  • The George W. Bush Presidential Center awarded Houston the No. 6 spot on its 2024 ranking of the top U.S. metro areas for university innovation.
  • A 2023 ranking from the LendingTree personal finance website put Houston in 13th place among the U.S. metro areas where minority entrepreneurs are enjoying the most success.
    “Houston’s reputation for entrepreneurship is inextricably linked to the city’s diversity,” the Understanding Houston website notes.

“The growing populations in Houston from diverse backgrounds, namely immigrants and people of color, are not only the economic and cultural driving force for the evolution of our city, but also the future of our country.”

The Texas Medical Center has named its second cohort for its United Kingdom-focused health tech accelerator. Photo via TMC

16 digital health, medical device companies selected for UK, TMC accelerator

coming to Hou

For the second time, an accelerator backed by the United Kingdom and hosted by Texas Medical Center Innovation has named 16 companies to its new cohort.

In partnership with Innovate UK, TMC named the new cohort companies in an announcement this week. The companies are divided into two categories — digital health and medical device — and cover a wide range of specialties, from diagnostics and AI monitoring to non-surgical management and more.

The accelerator launched last year with its inaugural cohort with the mission of helping companies make their United States expansion by way of the TMC.

"The first cohort of startups in our accelerator program experienced TMC's capabilities in developing and advancing solutions through cross-collaboration with top minds in clinical care, commercialization and innovation," Devin Dunn, head of the Accelerator for Health Tech at TMC, says in a news release. "We are excited to continue our partnership with Innovate UK and welcome this second cohort to continue our efforts advancing life sciences technologies across the globe."

This year's program begins June 4 and will run through November. According to the TMC, last year's cohort had significant success tapping into the health tech ecosystem in Houston, including engaging with investors, setting up a go-to-market strategy, and making inaugural U.S.-based hires.

“Our Global Incubator Programme selects driven and ambitious innovators looking to scale their technologies globally," adds Jon Hazell, partnership manager for the North America and Global Incubator at Innovate UK. "We are excited for our second cohort of startups to join the programme, supported by the Texas Medical Center accelerator, where world-class mentors and programming will help our entrepreneurs understand and meet the requirements of different markets, and build the necessary partnerships, collaborations, and networks, facilitating their entry into global markets."

The selected medical device companies — and their technologies, as described by the TMC — include:

  • Cytecom – infectious diagnostic test, powered by cutting-edge optical electrophysiology, detects resistant bacteria in just 45 seconds, enabling doctors to prescribe targeted antibiotics in minutes instead of days
  • Heartfelt Technologies Ltd – the future of heart failure telemonitoring an automatic, AI supported, non-contact telemonitoring solution for heart failure patients
  • Neurovalens Ltd – creates wearable neurostimulaton devices that treat a range of conditions in an entirely non-invasive and drug-free way
  • Oxford Medical Products Limited – a proprietary hydrogel pill that acts as a non-surgical, non-pharmacological obesity treatment that will redefine the obesity treatment market
  • Phenutest – a rapid point-of-care diagnostic test for urinary tract infection, that confirms infection and appropriate antimicrobial to prescribe within 60 minutes
  • Plexaa – world's first fully wearable, sensor controlled, bra insert that can deliver safe supraphysiological preconditioning to the breast skin the night before surgery at home
  • SolasCure Limited – a wound Gel that acts as a single, effective and easy-to-use solution to overcome the challenges to transform chronic wound care
  • Trueinvivo Limited – a proprietary dosimetry (radiation measurement) system to ensure the precision and accuracy of cancer radiotherapy

The selected digital health companies — and their technologies, as described by the TMC — include:

  • Axon Diagnostics – offers a suite of solutions to support the needs of modern day diagnostic imaging services, supporting happier lives for clinicians and helping deliver better diagnostic care for all
  • Kheiron Medical Technologies – regarded as a world leader in the development of AI-enabled cancer diagnostics and monitoring
  • KiActiv – a technology-enabled digital health model for behaviour change and self-care that rethinks exercise and makes everyday movement an effective personalized medicine for better clinical outcomes
  • Memory Lane Games – turns memories into games, offering care providers a simple, fun dementia engagement app designed to trigger positive memories and improve socialisation with caregivers and people living with dementia
  • NeuroVirt Limited – combines immersive VR, AI and computer vision to gamify rehabilitation and quantify patient impairment and improvement
  • Newton’s Tree – enables healthcare providers to procure, integrate, and monitor third party AI products as part of routine care pathways through its enterprise AI platform
  • SERG Technologies – uses patented sensor technology and artificial intelligence to transform disease management into a continuous, data driven, and patient specific approach for people with Parkinson’s
  • Thymia – leverages speech, video, and behavioral analytics gathered via specially designed video games to diagnose conditions like depression, anxiety, and ADHD, alongside critical symptoms like fatigue, mood fluctuations, and memory issues, creating novel mental health biomarkers
The partnership between the U.K. and TMC began in 2018 as a biobridge between the two entities. TMC has expanded into new biobridges with other countries — most recently with The Netherlands — and also has a Danish accelerator that's also running its second cohort this summer.
The Texas Medical Center visited the Netherlands to secure a deal that creates a BioBridge to the country and Houston. Photo courtesy of TMC

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

Insight Surgery is opening its first international location, and the UK company chose Houston for it. Photo via 3dlifeprints.com

UK personalized surgery startup rebrands, expands to US by way of Houston

crossing the atlantic

An innovative health tech company headquartered in the United Kingdom has made its entrance into the United States — and Houston's Texas Medical Center is where it's setting up shop.

The company, newly renamed to Insight Surgery — neé 3D LifePrints — was originally established in 2011 by Paul Fotheringham as a social enterprise to create 3D printed prosthetics for amputees in Kenya. While the company still provides this care to developing countries, Fotheringham, who serves as CTO, evolved his mission into a business in 2015. The company is gearing up for its next evolution — starting with its first international expansion.

“We’re pivoting away from being a 3D printing company toward a company that personalizes surgery,” Fotheringham tells InnovationMap.

Insight Surgery's focus now is to provide digital planning for surgeons and create personalized medical devices. All the technology the company is working with is FDA approved, but will be customized for patients and surgeons. Previously, this type of customized care could take weeks or months, Fotheringham says, but with Insight Surgery's technology, they can accomplish this in a matter of days.

“We’ve coupled this all together at the point of care by putting people and technology in the hospitals,” Fotheringham explains. “We are changing the norm about (traditional surgery)."

Fotheringham and his team connected with Texas Medical Center Innovation Hub by way of a biobridge — an initiative by TMC to work with international entities to provide an exchange of tech and innovative care. TMC originally launched this UK partnership in 2018 and has expanded it to other countries, including Ireland, Australia, and Denmark.

Insight Surgery is currently building out its 5,000-square-foot space in TMCi that will have a print room for manufacturing. Local operations will be led by David Collins, US engineering lead, who will collaborate with Houston medical professionals at the point of care.

"The US is about 45 percent of the global market for personalized devices, so for us it's part of our expansion — both revenue and investment. We're moving into our fourth round of investment, and the funds will be used for geographic expansion," Fotheringham says. "It's the right time. There's not a lot of competitors."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice University breaks ground on new innovation hub, The Arc

breaking ground

Construction is officially underway on Rice University's The Arc in Houston’s Ion District.

The university broke ground on the 200,000-square-foot research, corporate innovation and office building on Nov. 4. The facility will share a plaza with the existing Ion building, fostering collaboration within the innovation space, according to Rice.

“The Arc will bring Rice’s extraordinary research and talent and Houston’s impactful innovation ecosystem into even closer connection with the industries and innovators working to solve some of the world’s most consequential challenges,” Rice President Reginald DesRoches said in an announcement. “That constant exchange of ideas and expertise will help move discoveries more rapidly from the laboratory to real-world impact.”

Construction is scheduled to be completed by Q2 2028. Rice Real Estate Co. is developing the project, and Rice University will occupy about 80,000 square feet in the building (about 40 percent). Preleasing has begun, with floor plans ranging from 28,000 to 31,000 square feet.

The Arc will feature conference and meeting spaces, an amenity lounge, fitness center, outdoor plazas, underground parking, and on-site retail and dining, according to the release.

It aims to host tenants focused on artificial intelligence and machine learning, data science, robotics, quantum science and engineering and energy, including Rice's new AI Foundry.

Rice says the AI Foundry will be a space where university experts and partners can support organizations with AI challenges. Rice recently committed to hiring 75 new AI-focused faculty and announced plans to launch a new Master of Artificial Intelligence (MAI) next fall.

“The AI Foundry is exactly the kind of collaboration the Arc is designed to enable,” Amy Dittmar, the Howard R. Hughes Provost and executive vice president for academic affairs at Rice, added in the release. “By bringing Rice researchers together with industry partners in a shared environment, we can accelerate the movement of ideas from research into practical applications while helping organizations build the capabilities they need to succeed as AI continues to evolve.

Developers of The Arc are targeting LEED Gold certification by incorporating smart building automation and energy-saving features into the project's design. Rice first announced the project in September 2025.

Rendering courtesy Bogza

Houston battery tech startup FlowCellutions acquired by Katy energy co.

M&A

Katy-based TerraFlow Energy, an energy storage and infrastructure company, has acquired Houston-based battery technology startup FlowCellutions. Financial terms weren’t disclosed.

FlowCellutions still operates under its established name, but with the tagline “A TerraFlow Energy Company.” Becca Segel, founder and CEO of FlowCellutions, now runs the business as its president.

FlowCellutions specializes in electrochemical sensing, diagnostics, analytics, and testing that offer insights into battery chemistry, charging capabilities, and system performance.

“FlowCellutions has always been focused on developing better ways to understand what is happening inside a flow battery and using that information to improve how these systems perform,” Segal said in a press release. “Joining TerraFlow gives us the opportunity to apply that work at a much larger scale while continuing to build the capabilities and expertise that make FlowCellutions unique.”

The FlowCellutions platform supports data centers and other heavy users of power. It’s designed to help reduce operating costs, prevent failures and costly downtime, and extend battery lifetime from about seven years to more than 30 years.

Segel founded the company in 2022. A member of Greentown Labs, the company raised more than $2 million in non-dilutive funding and received $1.5 million in National Science Foundation funding earlier this year.

FlowCellutions is one of five finalists in the Energy Transition Business category of InnovationMap’s 2026 Houston Innovation Awards.

“FlowCellutions brings a depth of scientific and technical expertise that fits naturally with where TerraFlow is going,” Jon Parrella, CEO of TerraFlow, said in the release.

“As we move from developing these systems to deploying them at commercial scale, understanding performance at a deeper level matters,” he said. “Bringing FlowCellutions into TerraFlow strengthens that capability and gives both teams more opportunity to advance the technology.”TerraFlow, founded in 2024, develops long-duration energy storage and power infrastructure for data centers, industrial facilities, utilities and other large power consumers.

---

This article originally appeared on EnergyCapitalHTX.com.

3 fast-growing Houston scaleups named Innovation Awards finalists

meet the finalists

From IPOs to groundbreakings, some of Houston's most innovative companies reached major milestones this year.

As part of the 2026 Houston Innovation Awards, our Scaleup of the Year category honors innovative later-stage startups that have recently reached a significant milestone in company growth. Three scaleups have been named finalists for the 2026 award.

Read more about these businesses, their founders and their breakthrough technologies below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Erock

Energy infrastructure company Erock, previously known as Enchanted Rock, develops dual-purpose microgrids that rely on natural gas and renewable natural gas to produce lower carbon emissions and air pollutants than diesel generators. Its products can provide bridge power before grid interconnection, backup power during outages and dispatchable capacity that supports long-term grid reliability. The company has more than 1,100 megawatts of installed capacity and over 20 years of experience serving commercial, municipal and large-scale technology customers.

Erock completed its initial public offering this year, raising approximately $600 million in gross proceeds. It also grew its contracted power system sales backlog to approximately $1.7 billion, up tenfold year-over-year, with production sold out through 2028, according to the company's application. The company secured a major equipment order from Anthropic, began construction of the 366-megawatt El Paso Electric project supporting Meta's data center campus, and started assembly operations at its Hyperion facility in Cypress, Texas.

Hertha Metals

Hertha Metals produces lower-cost, lower-emission steel and high-purity iron. The company has developed a single-step process that uses natural gas as a direct reductant instead of metallurgical coal, which cuts production costs by more than 25 percent and emissions by up to 50 percent, according to the company. The same process produces high-purity iron needed for high-purity steels and rare earth magnets. The company says it aims to "re-industrialize America’s production of critical materials."

Hertha Metals was founded by CEO Laureen Meroueh in 2022 and emerged from stealth last year with more than $17 million in venture capital funding. The company closed a $133.65 million Series A this month and also broke ground on its $100M high-purity iron factory known as Chalyx in Conroe.

Venus Aerospace

Spacetech company Venus Aerospace is developing a high-thrust rotating detonation rocket engine (RDRE) that replaces the subsonic combustion used in conventional rocket engines. The RDRE is a compact, simpler engine that can deliver up to 15 percent greater efficiency for defense and space applications. It completed its first U.S. flight test of the engine last summer.

Venus Aerospace was founded in 2020 by CEO Cassie Duggleby and CTO Andrew Duggleby. It raised a $20 million Series A in 2022 and $42 million Series A2 in 2025. It closed a $91 million Series B earlier this year and expanded its leadership team. The company is working toward longer-duration and higher-thrust testing and advancing its flight program.